NCT02340572View on ClinicalTrials.gov

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

August 31, 2015

Conditions
Healthy
Interventions
DRUG

PRS-080#022-DP

hepcidin antagonist

DRUG

PRS-080-Placebo#001

Placebo treatment

Trial Locations (1)

Unknown

Nuvisan GmbH, Neu-Ulm

Sponsors
All Listed Sponsors
collaborator

Nuvisan Pharma Services

UNKNOWN

collaborator

FGK Clinical Research GmbH

INDUSTRY

collaborator

EUROCALIN Consortium

UNKNOWN

lead

Pieris Pharmaceuticals GmbH

INDUSTRY